Essential Premium

These Hedge Funds Benefit From Kenvue Deal

Several prominent funds, including Third Point, held significant stakes in the Tylenol owner before it agreed to be acquired by Kimberly-Clark.

The Debate Over Private Credit Returns Is Just Heating Up

Cliffwater is pushing back against a new study in the Journal of Private Markets Investing that shows the asset class doesn’t outperform public credit.

Sponsored

What’s Behind the Latest Surge in Grain and Oilseed Prices?

Greenlight’s October Rebound Fails to Close Gap With S&P

David Einhorn’s hedge fund rose 2.2 percent last month — its best showing since April — but remains far behind the broader market.

Related Content

The Hedge Fund Winners From Immunovant’s Rise

Stephen Taub

When the Hedges Don’t Hedge the Way You Expect

Julie Segal

Biopharma’s Remarkable Reversal of Fortune

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram